U.S. markets closed
  • S&P Futures

    4,124.25
    -0.25 (-0.01%)
     
  • Dow Futures

    32,747.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    13,020.25
    -11.25 (-0.09%)
     
  • Russell 2000 Futures

    1,913.90
    -0.70 (-0.04%)
     
  • Crude Oil

    90.24
    -0.26 (-0.29%)
     
  • Gold

    1,792.40
    -1.60 (-0.09%)
     
  • Silver

    20.45
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0219
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2080
    +0.0004 (+0.03%)
     
  • USD/JPY

    135.0100
    -0.1060 (-0.08%)
     
  • BTC-USD

    22,901.89
    -921.70 (-3.87%)
     
  • CMC Crypto 200

    531.97
    -25.38 (-4.55%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,767.07
    -232.89 (-0.83%)
     

Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Edwards Lifesciences Corp (NYSE: EW) reported second-quarter sales of $1.37 billion, flat compared to 2Q21, missing the consensus of $1.4 billion.

  • Adjusted EPS was $0.63, which missed the consensus of $0.64.

  • The adjusted gross profit margin was 80.5% for the quarter, compared to 75.9% in 2Q21.

  • Transcatheter aortic valve replacement sales grew to $907 million, up 1%. Globally, the company's average selling price and market position were stable.

  • Surgical Structural Heart sales were $229 million, down 4% Y/Y.

  • EW's cash, cash equivalents, and short-term investments totaled $1.5 billion as of June 30, 2022.

  • 3Q22 Guidance: Edwards Lifesciences expects revenue of $1.30 billion and $1.37 billion (consensus $1.44 billion) and adjusted EPS of $0.58 to $0.66 (consensus $0.65).

  • FY22 Guidance: Edwards Lifesciences expects sales of $5.35 billion to $5.55 billion (prior $5.5 billion - $6.0 billion) vs. consensus of $5.71 billion and adjusted EPS of $2.50 - $2.65 (consensus of $2.56).

  • Price Action: EW shares are trading lower by 5.86% at $101 during the post-market session on Thursday.

  • Photo via Wikimedia Commons

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.